JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


The Journal of Nuclear Medicine Vol. 35 No. 1 127-134
© 1994 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hnatowich, D.J.
Right arrow Articles by Rusckowski, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hnatowich, D.J.
Right arrow Articles by Rusckowski, M.

Investigations of Ascorbate for Direct Labeling of Antibodies with Technetium-99m

D.J. Hnatowich, F. Virzi, P. Winnard, Jr., M. Fogarasi and M. Rusckowski

Department of Nuclear Medicine, University of Massachusetts Medical Center, Worcester, Massachusetts

Correspondence: For correspondence or reprints contact: D.J. Hnatowich, PhD, Department of Nuclear Medicine, University of Massachusetts Medical Center, Worcester, MA 01655.

ABSTRACT

Recently, a method for the direct labeling of antibodies with 99mTc was described in which sulfhydryls were reportedly generated by reduction of antibody disulfides with ascorbic acid. Thereafter, these proteins may be labeled at high efficiency with 99mTc following reduction of pertechnetate with dithionite. This investigation was initially conducted to evaluate the mechanism of the increased stability towards cysteine challenge reported for the label and subsequently to determine the role of ascorbate in the labeling process. Methods: It was possible to reproduce the reported high labeling efficiencies by increasing the dithionite concentration fivefold, presumably because of variabilities among lots of commercial sodium dithionite. Results: Despite success in labeling, it was not possible to confirm that antibody reduction followed the treatment with ascorbate. Using both Ellman's reagent and 2,2' dithiodipyridine as indicators, we were unable to detect sulfhydryls on one IgG antibody treated at ten times the suggested ascorbate-to-antibody molar ratio. It was estimated that the number of sulfhydryls generated could not have been more than 1% (dithiodipyridine) to 2% (Ellman's). Furthermore, radiolabeling efficiencies for two IgG antibodies and stabilities of the label to cysteine challenge were unchanged when the ascorbate was eliminated. The number of sulfhydryls generated by treatment of the antibody with dithionite at 1–2 times the concentration required for adequate labeling was about 1% (dithiodipyridine) to 5% (Ellman's). Conclusion: For the conditions of this investigation and for the antibodies employed, ascorbate apparently played no more than a minor role at best in the labeling process. If antibody reduction occurred, this most likely was a result of residual dithionite presented to the protein along with the reduced 99mTc.

Key Words: Technetium-99m • antibodies • ascorbate




This article has been cited by other articles:


Home page
JNMHome page
Y.-M. Zhang, Y. Wang, N. Liu, Z.-H. Zhu, M. Rusckowski, and D. J. Hnatowich
In Vitro Investigations of Tumor Targeting with 99mTc-Labeled Antisense DNA
J. Nucl. Med., November 1, 2001; 42(11): 1660 - 1669.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1994 by the Society of Nuclear Medicine.